← Back to Clinical Trials
Recruiting NCT07512882

NCT07512882 Cohort of Patients With Chronic Myelomonocytic Leukemia

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07512882
Status Recruiting
Phase
Sponsor Gustave Roussy, Cancer Campus, Grand Paris
Condition Leukemia
Study Type OBSERVATIONAL
Enrollment 5,000 participants
Start Date 2026-05-05
Primary Completion 2040-03

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Sampling

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 5,000 participants in total. It began in 2026-05-05 with a primary completion date of 2040-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

A prospective, non-interventional study involving the collection of biological samples with associated anonymised data. Biological samples will be collected at the time of diagnosis and/or as the disease progresses, with or without treatment, always in conjunction with tests scheduled as part of routine care or within the context of a clinical trial.

Eligibility Criteria

Inclusion Criteria: * Adults aged 18 years and over * Blood monocytosis ≥ 0.5 × 10⁹/L and ≥ 10% of total white blood cells or * Confirmed diagnosis of chronic myelomonocytic leukemia * Regardless of stage (chronic or transformed), and whether or not currently being treated * Signed informed consent Exclusion Criteria: * Active, uncontrolled infection (particularly hepatitis B, hepatitis C, HIV) * Refusal informed consent

Contact & Investigator

Central Contact

Christophe WILLEKENS

✉ Christophe.willekens@gustaveroussy.fr

📞 +33 1 42 11 23 79

Frequently Asked Questions

Who can join the NCT07512882 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07512882 currently recruiting?

Yes, NCT07512882 is actively recruiting participants. Contact the research team at Christophe.willekens@gustaveroussy.fr for enrollment information.

Where is the NCT07512882 trial being conducted?

This trial is being conducted at Amiens, France, Angers, France, Antony, France, Bobigny, France and 11 additional locations.

Who is sponsoring the NCT07512882 clinical trial?

NCT07512882 is sponsored by Gustave Roussy, Cancer Campus, Grand Paris. The trial plans to enroll 5,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology